COSMOS HEALTH NEW DL-01 (V67A) - Net Assets
Based on the latest financial reports, COSMOS HEALTH NEW DL-01 (V67A) has net assets worth €18.42 Million EUR (≈ $21.54 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€65.48 Million ≈ $76.55 Million USD) and total liabilities (€47.05 Million ≈ $55.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore V67A total asset value for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.42 Million |
| % of Total Assets | 28.14% |
| Annual Growth Rate | 43.22% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 358.41 |
COSMOS HEALTH NEW DL-01 - Net Assets Trend (2021–2025)
This chart illustrates how COSMOS HEALTH NEW DL-01's net assets have evolved over time, based on quarterly financial data. Check COSMOS HEALTH NEW DL-01 (V67A) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for COSMOS HEALTH NEW DL-01 (2021–2025)
The table below shows the annual net assets of COSMOS HEALTH NEW DL-01 from 2021 to 2025. For live valuation and market cap data, see market value of COSMOS HEALTH NEW DL-01.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €18.42 Million ≈ $21.54 Million |
-24.90% |
| 2024-12-31 | €24.53 Million ≈ $28.68 Million |
-31.93% |
| 2023-12-31 | €36.04 Million ≈ $42.14 Million |
-9.11% |
| 2022-12-31 | €39.66 Million ≈ $46.36 Million |
+805.52% |
| 2021-12-31 | €4.38 Million ≈ $5.12 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to COSMOS HEALTH NEW DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9882176700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €151.59 Million | 822.77% |
| Total Equity | €18.42 Million | 100.00% |
COSMOS HEALTH NEW DL-01 Competitors by Market Cap
The table below lists competitors of COSMOS HEALTH NEW DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Decade Resources Ltd
V:DEC
|
$10.71 Million |
|
Portage Biotech Inc
NASDAQ:PRTG
|
$10.71 Million |
|
Zantat Holdings Berhad
KLSE:0301
|
$10.72 Million |
|
Pacific Horizon Investment Trust
LSE:PHI
|
$10.73 Million |
|
Adagio Medical Holdings, Inc Common Stock
NASDAQ:ADGM
|
$10.71 Million |
|
Great Divide Mining Ltd
AU:GDM
|
$10.71 Million |
|
Melbana Energy Ltd
AU:MAY
|
$10.70 Million |
|
Perpetual Resources Ltd
AU:PEC
|
$10.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COSMOS HEALTH NEW DL-01's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 24,532,929 to 18,424,629, a change of -6,108,300 (-24.9%).
- Net loss of 19,144,998 reduced equity.
- New share issuances of 5,417,396 increased equity.
- Other factors increased equity by 7,619,302.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-19.14 Million | -103.91% |
| Share Issuances | €5.42 Million | +29.4% |
| Other Changes | €7.62 Million | +41.35% |
| Total Change | €- | -24.90% |
Book Value vs Market Value Analysis
This analysis compares COSMOS HEALTH NEW DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.03x to 0.35x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €6.38 | €0.18 | x |
| 2022-12-31 | €3.74 | €0.18 | x |
| 2023-12-31 | €2.27 | €0.18 | x |
| 2024-12-31 | €1.04 | €0.18 | x |
| 2025-12-31 | €0.49 | €0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently COSMOS HEALTH NEW DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -103.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.33%
- • Asset Turnover: 1.00x
- • Equity Multiplier: 3.55x
- Recent ROE (-103.91%) is below the historical average (-87.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -181.80% | -14.16% | 1.14x | 11.29x | €-8.40 Million |
| 2022 | -34.88% | -27.47% | 0.74x | 1.72x | €-17.80 Million |
| 2023 | -51.45% | -34.74% | 0.81x | 1.83x | €-22.15 Million |
| 2024 | -65.96% | -29.73% | 1.00x | 2.21x | €-18.64 Million |
| 2025 | -103.91% | -29.33% | 1.00x | 3.55x | €-20.99 Million |
Industry Comparison
This section compares COSMOS HEALTH NEW DL-01's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $4,471,455,515
- Average return on equity (ROE) among peers: -23.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COSMOS HEALTH NEW DL-01 (V67A) | €18.42 Million | -181.80% | 2.55x | $10.71 Million |
| AKSO HEALTH GR. (SPADR)/3 (8HX) | $12.29 Million | -137.16% | 4.11x | $1.60 Billion |
| EDAP TMS S.A (EDA) | $25.16 Million | -2.71% | 0.86x | $128.94 Million |
| Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) | $37.77 Billion | 7.51% | 1.16x | $439.62 Million |
| CLOUDR GROUP LTD. (H3L) | $1.88 Billion | -89.77% | 0.51x | $40.39 Million |
| Medios AG (ILM1) | $341.07K | 0.00% | 1.52x | $312.19 Million |
| M1 Kliniken AG (M12) | $15.12 Million | 0.72% | 0.48x | $300.08 Million |
| Paragon Care Limited (PXS) | $72.77 Million | 10.35% | 1.03x | $129.66 Million |
| Sigma Healthcare Limited (S5YA) | $476.74 Million | -2.59% | 1.54x | $19.74 Billion |
| TELES Informationstechnologien AG (TLIK) | $-10.33 Million | 0.00% | 0.00x | $1.53 Million |
About COSMOS HEALTH NEW DL-01
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It als… Read more